Loading clinical trials...
Loading clinical trials...
Primary Objective: To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. porta...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanofi
NCT05992532 · Gaucher Disease, Acid SphingoMyelinase Deficiency
NCT06192576 · Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
NCT07274826 · Acid Sphingomyelinase Deficiency (ASMD)
NCT06949358 · Acid Sphingomyelinase Deficiency
NCT05641103 · Gaucher Disease, Acid SphingoMyelinase Deficiency, and more
Investigational Site Number 2500036
Amiens
Investigational Site Number 2500014
Angers
Investigational Site Number 2500034
Argenteuil
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions